secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001104659-25-007221
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics shareholders approve reverse stock split range of 1:5 to 1:30
--------------------------------------------------------------------------------

- Proposal 1 passed with ~90.8% of votes cast in favor (27.6M for, 2.5M against, 0.3M abstain).
- Proposal 2 (adjournment) also approved with ~91.5% of votes cast in favor (27.7M for).
- Board retains discretion to select exact split ratio between 1:5 and 1:30 at a later date.
- Approximately 61.2% of outstanding common stock (30.4M shares) was represented at the special meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925007221/0001104659-25-007221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925007221/tm254832d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-007221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer